Alpha thalassemia is diagnosed through a sequence of blood tests, starting with a basic blood count and potentially ending with genetic testing. Unlike beta thalassemia, which shows clear markers on standard hemoglobin tests, alpha thalassemia often requires DNA analysis for a definitive diagnosis. The testing process typically moves through three stages: initial blood work, hemoglobin analysis, and molecular confirmation.
Step 1: Complete Blood Count
The first clue usually comes from a routine complete blood count (CBC). Two measurements matter most: mean corpuscular volume (MCV), which reflects the size of your red blood cells, and mean corpuscular hemoglobin (MCH), which measures how much oxygen-carrying protein each cell contains. Both values run low in alpha thalassemia, even in mild forms.
People with alpha thalassemia trait (two deleted genes) typically have an MCV around 71.6 fL, well below the normal range of roughly 87 to 89 fL. Their MCH drops to about 22.9 pg compared to a normal value near 30 pg. Silent carriers (one deleted gene) show subtler changes: an MCV around 81 fL and MCH around 26 pg. These numbers overlap with iron deficiency anemia, which is where additional testing becomes important.
Telling It Apart From Iron Deficiency
Small, pale red blood cells can mean either thalassemia or iron deficiency, so distinguishing between the two is a key part of the workup. One quick tool is the Mentzer index: divide your MCV by your red blood cell count. A result below 13 suggests thalassemia, while a result above 13 points toward iron deficiency. The logic is straightforward. In thalassemia, your body produces a normal number of red blood cells, but they’re smaller than usual, pushing the ratio down. In iron deficiency, your body makes fewer cells overall.
An iron studies panel (ferritin, serum iron, and transferrin saturation) can further clarify things. If iron levels are normal and your red blood cells are still small, thalassemia moves higher on the list of possibilities.
Step 2: Hemoglobin Analysis
The next step is hemoglobin electrophoresis or high-performance liquid chromatography (HPLC). Both methods separate the different types of hemoglobin in your blood and measure each one’s percentage. This is where beta thalassemia typically shows up clearly, with elevated levels of a hemoglobin fraction called HbA2. Alpha thalassemia is trickier.
In Hemoglobin H disease (three deleted genes), these tests can detect an abnormal hemoglobin called HbH, which forms when leftover beta-globin chains clump together in groups of four. HPLC and electrophoresis can also pick up Hb Bart’s, another abnormal hemoglobin found in more severe forms. But in milder alpha thalassemia (one or two gene deletions), hemoglobin analysis often looks completely normal. The standard hemoglobin fractions come back in expected ranges, and there’s nothing unusual to flag. This is the main reason alpha thalassemia trait gets missed on routine screening and why genetic testing is frequently needed.
Step 3: Genetic (DNA) Testing
Molecular testing is the only way to definitively confirm alpha thalassemia and determine exactly how many of the four alpha-globin genes are affected. This matters for your own health management and, critically, for family planning if your partner also carries alpha thalassemia genes.
Gap-PCR
The most widely used method is called Gap-PCR. It works by targeting the specific stretches of DNA where known deletions occur. The test can identify the seven most common alpha-globin gene deletions found across different populations, including Southeast Asian, Filipino, Mediterranean, and Thai deletion types. It’s fast and relatively inexpensive, making it a good first-line molecular test. The limitation is that it only detects deletions it’s specifically designed to find. Rare or unusual deletions can slip through, and the test doesn’t work well with degraded DNA samples.
MLPA
A more comprehensive molecular option is MLPA (multiplex ligation-dependent probe amplification). This technique measures how many copies of the alpha-globin gene are present by counting specific DNA segments. It can detect both common and uncommon deletions, plus certain non-deletion mutations where the gene is present but doesn’t work properly. MLPA also handles older or partially degraded DNA samples better than Gap-PCR, which makes it useful in certain clinical situations. It’s typically ordered when Gap-PCR comes back negative but suspicion for alpha thalassemia remains high based on blood work.
What Each Gene Deletion Looks Like
The severity of alpha thalassemia depends on how many of your four alpha-globin genes are missing or nonfunctional. Testing aims to place you in one of four categories:
- One gene deleted (silent carrier): No symptoms. Hemoglobin levels are essentially normal (around 14.3 g/dL in men, 12.6 g/dL in women). Red blood cells may be slightly small. Standard blood tests rarely raise suspicion.
- Two genes deleted (alpha thalassemia trait): Mild anemia with noticeably small red blood cells. Hemoglobin runs around 13.9 g/dL in men and 12.0 g/dL in women. Often mistaken for iron deficiency. Hemoglobin electrophoresis is usually normal.
- Three genes deleted (Hemoglobin H disease): Moderate to severe anemia, with hemoglobin around 10.9 g/dL in men and 9.5 g/dL in women. HbH is detectable on hemoglobin analysis. Patients typically need ongoing medical monitoring.
- Four genes deleted (Bart’s hydrops fetalis): The most severe form. Hemoglobin drops to 3 to 8 g/dL, consisting almost entirely of Hb Bart’s. This condition is usually fatal before or shortly after birth without intervention.
The two-gene deletion category has an important subtlety. You can lose one gene from each chromosome (called alpha-plus on both sides) or both genes from the same chromosome (called alpha-zero on one side). The blood tests look identical, but the genetic implications for future children are very different. Only DNA testing can tell these apart.
Newborn Screening
Alpha thalassemia is not part of the standard recommended newborn screening panel in the United States, but it often gets detected anyway. The methods used to screen for sickle cell disease, a core screening condition, also pick up Hb Bart’s. As of 2016, 93% of state newborn screening programs reported these results when found.
The percentage of Hb Bart’s detected at birth correlates directly with severity. Silent carriers show 1% to 3%, alpha thalassemia trait shows 3% to 6%, and Hemoglobin H disease shows 5% to 30%. This is a narrow window for detection: Hb Bart’s disappears from the blood after age one, so newborn screening is the only time it can be caught through routine hemoglobin testing in milder forms. Programs typically use isoelectric focusing or HPLC as their primary screening method, with the other technique used as confirmation.
Prenatal Testing
Couples who both carry alpha thalassemia genes may want prenatal testing to assess the baby’s risk for severe forms. Gap-PCR can be performed on fetal DNA, either from a traditional sample obtained during pregnancy or from cell-free fetal DNA circulating in the mother’s blood. The cell-free approach is less invasive and can be done earlier, though it’s not yet universally available. Prenatal testing is most important when both parents carry alpha-zero deletions (both missing genes on the same chromosome), since this combination creates a 25% chance of Bart’s hydrops fetalis in each pregnancy.
Why Alpha Thalassemia Is Often Missed
The fundamental challenge with alpha thalassemia testing is that the mildest and most common forms produce almost no abnormalities on standard lab work. A silent carrier has normal hemoglobin levels and nearly normal red blood cell size. Alpha thalassemia trait looks like iron deficiency on a CBC, and hemoglobin electrophoresis comes back normal. Without genetic testing, these carriers have no way of knowing their status. This is why targeted screening is recommended for people with ancestry from regions where alpha thalassemia is common, including Southeast Asia, southern China, the Middle East, Africa, and the Mediterranean. If your CBC consistently shows small red blood cells that don’t respond to iron supplements, and your hemoglobin electrophoresis is unremarkable, DNA testing for alpha-globin gene deletions is the logical next step.